孟鲁司特钠联合吸入舒利迭在支气管哮喘治疗中的作用观察

Observation on the Effect of Montelukast Sodium Combined with Seretide Inhalation in the Treatment of Bronchial Asthma

目的探讨孟鲁司特钠联合吸入舒利迭在支气管哮喘治疗中的应用效果。方法选择2017年1月至2019年1月入组接受治疗的82例支气管哮喘病患为对象进行治疗对比,依据以上病患的入院顺序分组,对照组41例使用舒利迭进行治疗,观察组41例则在对照组用药之上联合使用孟鲁司特钠进行治疗,对比治疗效果。结果比较两组治疗效果,观察组为97.6%显著优于对照组(P<0.05)。治疗前两组肺功能指标以及外周细胞因子指标的对比均未见明显差异(P>0.05),治疗后用力肺活量、第一秒用力呼气容积、自测呼气峰值流速等肺功能指标以及IL-13、IL-12、IFN-γ等指标的对比则均提示观察组更优(P<0.05)。治疗期间两组患者均未见明显不良反应。结论在支气管哮喘临床治疗工作当中应用孟鲁司特钠、舒利迭等药物进行治疗可得到良好的治疗效果,有利于改善患者肺功能,应用价值较高。

Objective To investigate the effect of montelukast sodium combined with Seretide inhalation in the treatment of bronchial asthma.Methods 82 patients with bronchial asthma who were admitted to the treatment group from January 2017 to January 2019 were selected for treatment comparison.According to the order of admission,41 patients in the control group were treated with seretide,while 41 patients in the observation group were treated with montelukast sodium on the basis of the control group.Result Compared with the two groups,97.6%in the observation group was significantly better than that in the control group(P<0.05).There was no significant difference in pulmonary function index and peripheral cytokine index between the two groups before treatment(P>0.05).The comparison of pulmonary function index such as forced vital capacity,forced expiratory volume in the first second,peak expiratory flow rate and IL-13,IL-12 and IFN-gamma after treatment indicated that the observation group was better(P<0.05).During the treatment period,no obvious adverse reactions were observed in both groups.Conclusion In the clinical treatment of bronchial asthma,the use of montelukast sodium,seretide and other drugs can obtain good therapeutic effect,which is conducive to improving the lung function of patients,and has a higher application value.